30 closest matches · ranked by relevance
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Lymphoma, Mucosa-Associated Lymphoid Tissue
Primary: Event-free-survival (EFS) — 51; 68; 51 percentage of patients
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Mantle-Cell Lymphoma
Primary: Progression-Free Survival (PFS) — 8 years
Lymphoma
Primary: Rate of Immunological Response to Vaccination — 0; 15 participants
Mantle Cell Lymphoma · Lymphoma, Mantle Cell
Primary: Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R) — 23.5…
Mantle Cell Lymphoma
Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg
Lymphoma
Primary: Progression-free Survival — 90 percentage of participants
Lymphoma
Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Marginal Zone Lymphoma
Primary: Overall Rate of Response (ORR) in Participants Receiving Protocol Therapy. — 87.5 percentage of participants
Lymphoma
Primary: Overall Survival at 100 Days Post Transplant (Number of Surviving Participants) — 16; 19 participants
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Marginal Zone Lymphoma · B-cell Lymphoma
Primary: ORR (Overall Response Rate) — 46 Percentage of Participants
Lymphoma
Primary: Progression-Free Survival (PFS) — 4.8; 3.7; 1.8 months — p=<0.0001
Mantle Cell Lymphoma
Primary: Overall Response Rate — 92 percentage of patients
Lymphoma
Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants Achieving CR or PR at the End of Therapy — 75.0; 92.4 percentage of participants — p=0.0009
Untreated Mantle Cell Lymphoma
Primary: Number of Participants With Toxicity — 8 participants
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) — 39.5 percentage of participants
T Cell Lymphoma
Primary: The Primary Efficacy Endpoint for This Study is Overall Regressive Response Rate (ORRR): Proportion of Patients With a Best Response of Complete Response (CR), Partial…
Lymphoma
Primary: Progression-free Survival Rate — 91; 78; 69 percentage of participants